Therapeutic approaches to protein-misfolding diseases
暂无分享,去创建一个
[1] W. Welch,et al. Manipulating the Folding Pathway of ΔF508 CFTR Using Chemical Chaperones , 2002 .
[2] J. Kelly,et al. Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.
[3] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[4] Jian‐Qiang Fan. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. , 2003, Trends in pharmacological sciences.
[5] P. Zeitlin,et al. Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. , 2002, Advanced drug delivery reviews.
[6] Pauline M. Rudd,et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity , 2001, Nature.
[7] S. Angers,et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.
[8] M. Bouvier,et al. Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation , 2002, The EMBO journal.
[9] P. Lansbury,et al. Amyloid fibrillogenesis: themes and variations. , 2000, Current opinion in structural biology.
[10] J. Collinge,et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease , 2003, Nature.
[11] James C. Sacchettini,et al. Therapeutic strategies for human amyloid diseases , 2002, Nature Reviews Drug Discovery.
[12] M. Wolfe. Secretase as a target for Alzheimer's disease. , 2002, Current topics in medicinal chemistry.
[13] J. Swatton,et al. Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. , 1999, The Biochemical journal.
[14] D. Lomas,et al. Alpha1-antitrypsin deficiency--a model for conformational diseases. , 2002, The New England journal of medicine.
[15] C. Lemere,et al. The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. , 2002, Vaccine.
[16] D. Perlmutter,et al. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[17] Satoshi Ishii,et al. Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.
[18] P. Lansbury,et al. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.
[19] J. Kelly,et al. Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[20] Chao Quan,et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. , 2003, Bioorganic & medicinal chemistry.
[21] Robert J. Desnick,et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. , 2001, The New England journal of medicine.
[22] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Kelly,et al. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Kelly,et al. Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins , 2001, Protein science : a publication of the Protein Society.
[25] F. Itoh,et al. The Antisense Approach in Amyloid Light Chain Amyloidosis: Identification of Monoclonal Ig and Inhibition of Its Production by Antisense Oligonucleotides in In Vitro and In Vivo Models1 , 2002, The Journal of Immunology.
[26] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[27] F. Heppner,et al. Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies , 2001, Science.
[28] J. Kelly,et al. Alternative conformations of amyloidogenic proteins govern their behavior. , 1996, Current opinion in structural biology.
[29] B. Solomon. Anti-aggregating antibodies, a new approach towards treatment of conformational diseases. , 2002, Current medicinal chemistry.
[30] S. Weggen,et al. Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease , 2002 .
[31] Fred E. Cohen,et al. Folding of Prion Protein to Its Native α-Helical Conformation Is under Kinetic Control* , 2001, The Journal of Biological Chemistry.
[32] F. Cohen,et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Kelly,et al. Amyloid as a natural product , 2003, The Journal of cell biology.
[34] S. Kaushal,et al. Pharmacological Chaperone-mediated in Vivo Folding and Stabilization of the P23H-opsin Mutant Associated with Autosomal Dominant Retinitis Pigmentosa* , 2003, The Journal of Biological Chemistry.
[35] Shuxia Zhao,et al. The Binding Site for Channel Blockers That Rescue Misprocessed Human Long QT Syndrome Type 2 ether-a-gogo-related Gene (HERG) Mutations* , 2002, The Journal of Biological Chemistry.
[36] C. Anfinsen. Principles that govern the folding of protein chains. , 1973, Science.
[37] F E Cohen,et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Vassar,et al. β-Secretase (BACE) as a drug target for alzheimer’s disease , 2002 .
[39] Rw Carrell,et al. Mechanisms of disease - Alpha(1)-antitrypsin deficiency - A model for conformational diseases , 2002 .
[40] M. Findeis,et al. Peptide inhibitors of beta amyloid aggregation. , 2002, Current topics in medicinal chemistry.
[41] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[42] A. Fersht,et al. Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations , 2000, The EMBO journal.
[43] J. Greer,et al. Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor , 2003, Journal of Pharmacology and Experimental Therapeutics.
[44] K. Fiebig,et al. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. , 2003, Journal of medicinal chemistry.
[45] D. Westaway,et al. Assembly of Alzheimer's amyloid-beta fibrils and approaches for therapeutic intervention. , 2001, Amyloid: Journal of Protein Folding Disorders.
[46] Christopher M. Dobson,et al. Amyloid fibrils from muscle myoglobin , 2001, Nature.
[47] Ernest Beutler,et al. Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[48] F. Cohen,et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein , 1995, Cell.
[49] J. Kelly,et al. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.